Results 61 to 70 of about 2,387 (195)

Impact van nirsevimab op pediatrische RSV-infecties in België in 2024-2025. Een analyse van de routine sentinel-surveillancegegevens van Sciensano

We schatten dat 35 tot 45% van de ziekenhuisopnames is voorkomen door de introductie van nirsevimab. We schatten dat de introductie van nirsevimab heeft geleid tot 35-45% minder ziekenhuisopnames voor een RSV-infectie bij kinderen jonger dan 5 jaar.
T. Braeye, A. Lajot, L. Cornelissen, L. De Mot, S. Hanoteaux, Y. Dockx, B.E.L.S.A.R.I.N.E.Tresearch group, S. Denayer, Y. Lafort, I. Van Evercooren, M. Fonnesu, Y. Dupont, K. Blot, M. Vandromme, P. Mpakaniye, M.U. Paz   +15 more
core   +1 more source

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France

The Lancet Microbe
Summary: Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants. Nirsevimab, a long-acting monoclonal antibody targeting a conserved epitope on the prefusion F protein (site Φ), has shown high ...
ProfPhD Slim Fourati, Alawiya Reslan, PhD, Jérôme Bourret, PhD, Jean-Sébastien Casalegno, PhD, Yannis Rahou, Laurent Softic, PhD, Lionel Chollet, MD, Pauline Trémeaux, PhD, ProfPhD Berthe-Marie Imbert-Marcille, PhD, Sylvie Pillet, PhD, Nicolas Veyrenche, PhD, Agathe Boudet, PhD, Luc Deroche, MD, ProfPhD Sonia Burrel, MD, Lina Mouna, PharmD, Theophile Cocherie, MD, Aurélie Schnuriger, PhD, Charlotte Pronier, PhD, Lynda Handala, PharmD, Véronique Brodard, PhD, Floriane Gallais, PhD, Sylvie Larrat, PhD, Alexandre Regueme, PharmD, Nefert Candace Dossou, PharmD, Amandine Henry, PharmD, ProfPhD Elyanne Gault, PharmD, Cédric Hartard, PhD, Ségolène Brichler, PhD, Alice Moisan, PhD, ProfPhD Véronique Avettand-Fenoel, PhD, Caroline Lefeuvre, PharmD, Ilka Engelmann, PhD, ProfPhD Sandrine Castelain, PhD, Audrey Mirand, PhD, Maud Salmona, PhD, Marie-Christine Jaffar-Bandjee, PhD, Mohamed Ader, Sarah Seng, Pierre Cappy, PhD, ProfPhD Christophe Rodriguez, PhD, Arnaud Ly, Georges Dos Santos, PhD, ProfPhD Olivier Schwartz, PhD, Chloé Petiot, Delphine Planas, PhD, Samar Berreira Ibraim, PhD, Kévin Da Silva, PhD, Amélie Recoing, MD, ProfPhD Jean-Michel Pawlotsky, MD, Frédéric Lemoine, PhD, ProfPhD Etienne Audureau, PhD, ProfPhD Marie-Anne Rameix-Welti, PhD, Naël Zemali, Sonia Burrel, Pantxika Bellecave, Alice Moisan, Zakasoa-Mbololona Zavaoarisaina, Romain Legros, Boris Derman, Vincent Pargny, Hortense Petat, Jean-Christophe Plantier, Véronique Avettand-Fenoel, Salim Ferrani, Jérome Guinard, Clémence Guillaume, Gilbert Mchantaf, Victoria Marie, Laurent Bret, Fabien Lesne, Anthony de Oliveira, Alexandre Regueme, Kazali Alidjinou, Lionel Chollet, Vincent Gardan, Ségolène Brichler, Loic de Pontual, Camille Aupiais, Stéphane Marot, Aurélie Schnuriger, Marine Perrier, Pierre Jatteau, Djeneba Fofana, Théophile Cocherie, Elisa Teyssou, Cathia Soulié, Vincent Calvez, Sylvie Larrat, Anne Faisant, Guillaume Mortamet, Caroline Tournegros, Mohamed Habib, Sylvie Pillet, Aymeric Cantais, Franck Zekre, Thomas Bourlet, Oulfa Boussetta-Charfi, Sara Chenafi-Adham, Eva Gleizes, Cédric Hartard, Caroline Lefeuvre, Elise Bouthry, Lina Mouna, Fairly Warnakulasuriya, Quentin Le Hingrat, Marie-Christine Jaffar-Bandjee, Diana Heaugwane, Benjamin Azemar, Nicolas Mnemosyme, Laurent Souply, Catherine François, Sandrine Castelain, Cinthia Rames, Arnaud Bécourt, Ilka Engelmann, Eric Jeziorski, Vincent Foulongne, Lynda Handala, Catherine Gaudy-Graffin, Agathe Crémadés, Amandine Henry, Alessandra Pennisi, Maud Salmona, Jérôme Le Goff, Audrey Gabassi, Marie-Laure Néré, Marine Minier, Audrey Baron, Stéphane Bonacorsi, Naim Ouldali, Abdeljalil Senhaji Rachik, Marie-Anne Rameix-Welti, Alawyia Reslan, Yannis Rahou, Banujaa Jeyarajah, Anne Huard de Verneuil, Jérome Bourret, Frédéric Lemoine, Kévin Da Silva, Samar Berreira Ibraim, Vincent Enouf, Danielle Perez-Bercoff, Lucy Mosscrop, Etienne Simon-Loriere, Nefert Candace Dossou, Astrid Vabret, Slim Fourati, Christophe Rodriguez, Jean-Michel Pawlotsky, Pierre Cappy, Alexandre Soulier, Mohamed Ader, Sarah Seng, Arnaud Ly, Amandine Caillault, Pierre-André Natella, Etienne Audureau, Georges Dos Santos, Laurence Fagour, Anne-Julie Schapira, Olivier Flechelles, Luc Deroche, Nicolas Lévêque, Claire Morton Fauche, Sarah Borel, Erwan Ripley, Juliette Aubin, Berthe-Marie Imbert, Louise Castain, Audreay Rodallec, Justine Sourice, Christele Gras-Le Guen, Anne Chauvire-Drouard, Elyanne Gault, Frédérique Moreau, Claire Deback, Floriane Gallais, Morgane Solis, Valentin Stephan, Léa Pilorgé, Sophie Vallet, Léa Gaitan, Sylvie Rogez, Audrey Mirand, Cecile Henquell, Charlotte Pronier, Claire Grolhier, Vincent Thibault, Pauline Trémeaux, Isabelle Claudet, Mélanie Pucelle, Laetitia Staes, Camille Vellas, Sofia Demmou, Romain Carcenac, Nicolas Veyrenche, Jean-sébastien Casalegno, Alexandre Gaymard, Jose Kombou, Antonin Bal, Stanislas Ogoudjobi, Agathe Boudet, Amélie Recoing   +202 more
doaj   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract disease, and the standard prevention strategy in Japan is limited to high-risk infants.
Shinichi Noto, Alexia Kieffer, Samira Soudani, Takeshi Arashiro, Chiho Tadera, Sebastien Eymere, Tobiasz Lemański, Xinyu Wang   +7 more
doaj   +1 more source

Efectividad de la inmunización con nirsevimab en neonatos para prevenir hospitalizaciones por virus respiratorio sincitial durante dos temporadas en Navarra

Anales del Sistema Sanitario de Navarra
Fundamento. La infección por el virus respiratorio sincitial (VRS) es la principal causa de hospitalización en lactantes. En 2022 se autorizó el nirsevimab en la Unión Europea para prevenir la enfermedad respiratoria grave por VRS durante el primer año ...
Noelia Vera-Punzano, Ana Navascués, Leticia Armendáriz, Natividad Viguria, Mercedes Herranz-Aguirre, Manuel García Cenoz, Camino Trobajo-Sanmartín, Aitziber Echeverria, Iván Martínez-Baz, Carmen Ezpeleta, Guillermo Ezpeleta, Jesús Castilla   +11 more
doaj   +1 more source

Palivizumab for Donor‐Derived RSV Infection in an Adult Bilateral Lung Transplant Recipient: A Case Report

Respirology Case Reports, Volume 14, Issue 8, August 2026.
We describe the use of off‐label palivizumab in an early post‐operative bilateral lung transplant recipient with probable donor‐derived RSV who developed persistent severe LRTI and respiratory failure. RSV PCR Ct fell and remained low from day 0 to day 42 despite conventional therapy until palivizumab was administered on day 44, following which we ...
Rosemary Meharry, Cassandra Vale, John Mackintosh   +2 more
wiley   +1 more source

Real-world impact of nirsevimab on RSV hospitalizations in children under 2 years of age: retrospective monocentric study in a large German tertiary pedatric center

Molecular and Cellular Pediatrics
Background Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization among infants and young children. Broad immunization with the monoclonal antibody nirsevimab represents a promising preventive strategy. However, real-world data
Moritz Bauer, Anke Wendt, Marcus A. Mall, Horst von Bernuth, Stephanie Thee   +4 more
doaj   +1 more source

Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis

Frontiers in Immunology
BackgroundRespiratory Syncytial Virus (RSV) is one of the primary pathogen responsible for severe lower respiratory tract infections in preterm infants, placing a significant burden on patients, their families, and society.
Xiaopeng Wang, Xiaopeng Wang, Xiaopeng Wang, Li Kong, Li Kong, Li Kong, Xueou Liu, Panpan Wu, Panpan Wu, Panpan Wu, Lulu Zhang, Lulu Zhang, Lulu Zhang, Fangrui Ding, Fangrui Ding, Fangrui Ding   +15 more
doaj   +1 more source

Results From the Third and Fourth WHO External Quality Assessments for the Molecular Detection of Respiratory Syncytial Virus

Influenza and Other Respiratory Viruses, Volume 20, Issue 8, August 2026.
ABSTRACT Background In 2016, the World Health Organization (WHO) initiated the global RSV surveillance programme, which aimed to strengthen laboratory diagnostic capacity and evaluate molecular detection test performance. External quality assessments (EQAs) are conducted regularly as part of this programme to ensure ongoing laboratory proficiency.
Fernando do Couto Motta, Obadiah Kenji, Ian Barr, Shabana Bi, Anne von Gottberg, Jean‐Michel Heraud, Siddhi Hirve, Sanjiv Rughooputh, Nicole Wolter, Maria Zambon, Thomas C. Williams, Wenqing Zhang   +11 more
wiley   +1 more source

Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023–2024 Season in Andalusia, Spain (NIRSEGRAND)

Vaccines
Background: Nirsevimab was indicated in a population level for all infants < 6 months during the 2023–2024 season in Andalusia (southern Spain). Our aim was to analyse the effect of nirsevimab in the reduction in complications in infants hospitalised for
David Moreno-Pérez, Aleksandra Korobova, Francisco de Borja Croche-Santander, Ana Cordón-Martínez, Olga Díaz-Morales, Leticia Martínez-Campos, Elena Pérez-González, María del Carmen Martínez-Padilla, Juan Luis Santos-Pérez, Jaime Brioso-Galiana, María Isabel Sánchez-Códez, Jorge Del Diego-Salas, Mario Rivera-Izquierdo, Nicola Lorusso   +13 more
doaj   +1 more source